UNITY Biotechnology Appoints Mike Sapieha, Ph.D., as Chief Scientific Advisor
Retrieved on:
Monday, February 1, 2021
UNITY also names Jason Damiano, Ph.D., as vice president of translational biology and Nathan Guz, Ph.D., as vice president of operations
Key Points:
- UNITY also names Jason Damiano, Ph.D., as vice president of translational biology and Nathan Guz, Ph.D., as vice president of operations
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced the appointment of Przemyslaw (Mike) Sapieha, Ph.D., as chief scientific advisor. - Mike is a long-term UNITY collaborator and an outstanding scientist whose work on the biological pathways impacting age-related eye diseases has been instrumental in the advancement of our Bcl-xL inhibitor, UBX1325, into the clinic, said Anirvan Ghosh, Ph.D., chief executive officer of UNITY.
- I am looking forward to joining Anirvan and the UNITY team to contribute to the realization of that vision.
- I am pleased to welcome Mike, Jason, and Nate to our leadership team as we drive UNITY forward.